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The expression of HER-2/neu (ErbB-2) is without
doubt predictive for the response of breast tumours to
the antibody trastuzumab. With regard to chemother-
apy and endocrine therapy the pattern is not so clear
cut. There are increasing data that appear to indicate
HER-2/neu is associated with a reduced sensitivity to
tamoxifen or alkylating agents and an enhanced sensi-
tivity to anthracyclines. However, it is not completely
clear whether protein overexpression or DNA ampliﬁ-
cation is the more appropriate measure, when HER-2/
neu status is used for predictive purposes. Further, data
derived from few existing studies are not always
consistent.
There is some evidence that HER-2/neu-positive tu-
mours are less responsive to tamoxifen therapy, al-
though the mechanism of this tamoxifen resistance is
not well understood. The ﬁrst randomised trial giving
evidence of an association of HER-2/neu with tamoxifen
resistance was the Italian Gruppo Universitario Nato-
letano-Trial (GUN) [1] that has been updated recently.
In this trial, 433 breast cancer patients were randomised
to receive either two years of adjuvant tamoxifen treat-
ment or no treatment. Although the ﬁnal analysis
showed a signiﬁcant beneﬁt for the tamoxifen-arm, a
subset analysis revealed that patients with HER-2/neu-
positive tumours did not beneﬁt from the tamoxifen
treatment.
A large study comparing diﬀerent endocrine therapies
was published by Ellis and colleagues [2]. In this ran-
domised, neoadjuvant, double-blinded trial, 278 patients
that had received either tamoxifen or the aromatase
inhibitor, letrozole, underwent core-needle biopsies to
asses their HER-2/neu (ErbB-2) and ErbB-1 tumour
status. The response rate to letrozole was superior to
tamoxifen (60% vs. 41% P=0.004). It has to be empha-
sised that this diﬀerence was due to a remarkable higher
response rate in those patients with ErbB-1- and HER-2/
neu (ErbB-2)-positive tumours (88% for letrozole vs.
21% for tamoxifen, P=0.0004). The diﬀerence in re-
sponse rates for ErbB-1- and HER-2/neu (ErbB’-nega-
tive tumours was not statistically signiﬁcant (54% for
letrozole vs. 42% for tamoxifen, P=0.078). A possible
explanation suggested by the author was that tamoxifen
resistance can be overcome by an eﬃcient estrogen de-
privation therapy. Recently reported data from the
Immediate Preoperative Arimidex tamoxifen or Com-
bined with Tamoxifen (IMPACT) trial on the aromatase
inhibitor, anastrozole, adds supporting evidence for this
theory [3].
The study from Ellis and colleagues [2] showed an-
other remarkable result: the superiority of letrozole over
tamoxifen was most marked in tumours that were
weakly ER-positive. The aromatase inhibitor presented
a response rate of 30% in tumours with an Allred Score
of 3–5, while no tumour scoring in this group responded
to tamoxifen.
Recent data presented by Syratos and colleagues [4]
indicates that HER-2/neu expression is associated with
lower oestrogen (ER) and progesterone receptor (PR)
levels. There was a signiﬁcant relationship between
HER-2/neu-positivity and the degree of ER-positivity,
as determined by quantitative measurement in fmol/mg.
Tumours that were HER-2/neu-positive showed lower
quantitative ER levels compared with HER-2/neu-
negative tumours, and the same diﬀerence was observed
for high-HER-2/neu overexpressers compared with low-
HER-2/neu overexpressers. Similar results were pre-
sented by Konecny and colleagues [5] in an even larger
clinical cohort.
If there is a quantitative inverse relationship between
HER-2/neu expression and ER levels on one hand and a
correlation between the response to tamoxifen and the
absolute ER levels on the other, this could explain the
partial tamoxifen resistance of HER-2/neu-positive tu-
mours and the superiority of aromatase inhibitors in this
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subset of patients. This data indicates that quantitative
measurement of the ER could not only be a more ap-
propriate way to predict the response to endocrine
treatment, but a predictor for the kind of treatment as
well. Meanwhile the question of whether or not HER-2/
neu (ErbB-2) tumour tissue measurements are useful for
selection of the most eﬃcacious endocrine therapy could
become redundant in the near future by the fact that
aromatase inhibitors are emerging as the ﬁrst the choice
endocrine therapy for hormone receptor-positive breast
cancer patients in the metastatic, neoadjuvant and ad-
juvant settings. This underlines the importance of HER-
2/neu (ErbB-2) determination in tumour tissues collected
from patients treated in large ongoing endocrine therapy
trials, like Arimidex, tamoxifen, alone or in combination
(ATAC), Tamoxifen and Exemestan Adjuvant Multi-
center trial (TEAM) and the Breast International Group/
Femara Tamoxifen Trial (BIG FEMTA), as it might be
our last chance to conﬁrm the role of HER-2/neu (ErbB-
2) as a predictive factor for speciﬁc endocrine therapies.
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